Eomesodermin expression in CD4⁺T-cells associated with disease progression in amyotrophic lateral sclerosis

Area of Science:

• Immunology
• Neuroscience
• Biomarker Discovery

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with complex immunopathological mechanisms.
• Understanding T-cell subset shifts and their role in ALS pathogenesis is crucial for developing effective biomarkers and therapies.

Purpose of the Study:

• To investigate the role of Eomesodermin (EOMES) as a potential biomarker in ALS.
• To elucidate the association between CD4+ T-cell subsets expressing EOMES and disease progression in ALS patients.

Main Methods:

• Quantification of T-cell subsets and EOMES expression using multicolor flow cytometry in 148 ALS patients and 101 healthy controls.
• Measurement of serum neurofilament light chain (NFL) levels.
• Longitudinal follow-up to assess disease progression rates and prognosis.

Main Results:

• Elevated proportions of CD4+EOMES+ T-cells were observed in ALS patients compared to healthy controls.
• Higher EOMES expression correlated positively with increased serum NFL levels and faster disease progression rates.
• Increased CD4+EOMES+ T-cell subsets were associated with a poorer prognosis in ALS.

Conclusions:

• Increased CD4+EOMES+ T-cell subsets represent a significant finding in ALS, linked to disease advancement and adverse outcomes.
• EOMES may serve as a valuable biomarker for monitoring ALS progression and patient prognosis.
• These findings contribute to a deeper understanding of the immune system's involvement in ALS pathogenesis.